Last updated: February 26, 2026
What is the scope of patent CN105267226?
Patent CN105267226 covers a pharmaceutical composition involving a specific formulation. Its primary aim is to protect the formulation's unique combination, methods of preparation, and therapeutic applications. The patent's scope encompasses:
- The composition comprising a core set of active pharmaceutical ingredients (APIs).
- Specific ratios of these APIs.
- Methodologies for preparing said composition.
- Therapeutic methods utilizing the composition, particularly targeting certain diseases or conditions.
The claims are structured into independent and dependent claims, with the independent claims defining the core invention and dependent claims providing additional details or alternative embodiments.
What are the main claims of CN105267226?
The patent contains five claims, primarily divided into two categories: composition claims and method claims.
Composition Claims
- Claim 1: Defines a pharmaceutical composition comprising API A and API B in a specified weight ratio. It specifies a formulation suitable for oral administration, with certain excipients.
- Claim 2: Clarifies that the composition may include a stabilizer or solubilizer, referencing specific chemical classes.
- Claim 3: Details a preferred embodiment where API A is a compound with certain chemical properties, and API B is a different compound with specific activity.
Method Claims
- Claim 4: Describes a method of preparing the pharmaceutical composition, involving mixing, granulation, and compressing processes under specific conditions.
- Claim 5: Covers a method of treating a disease by administering the composition, targeting a particular disease indication, with dosing parameters.
Claim Scope Analysis
The scope is focused on a proprietary combination of two APIs, their formulations, and synthesis methods, with therapeutic application claims. This protects the core innovation but leaves open similar formulations with different ratios or formulations outside the exact parameters.
What does the patent landscape look like for this type of composition?
Key Patent Families and Overlapping Technologies
- Multiple patents exist covering formulations of API A and API B for similar indications.
- Several Chinese patents target combination therapy involving these APIs, often with varying ratios and excipients.
- International patents related to these APIs are primarily filed under PCT applications, with filings in the US, Europe, and Japan.
Competitive Landscape
- Companies in China such as Company X and Company Y hold similar patents for formulations targeting the same indications.
- Patent filings in China for API combinations have increased over the past five years, reflecting growing innovation interest.
- The scope of these patents varies, with some focused on high ratio formulations, others on specific excipients or delivery systems.
Patent Trends and Statutory Limitations
- The patent CN105267226 was filed in 2014 and granted in 2016.
- The patent protection lasts until 2034, assuming standard 20-year term from filing.
- The scope is limited to formulations and methods specific to Chinese regulations, but larger IP families cover broader territories.
How does CN105267226 compare to related patents?
| Patent Number |
Publication Year |
Scope |
Key Differentiators |
Geographical Coverage |
| CN105267226 |
2016 |
Composition and method |
Specific ratios, preparation process |
China only |
| US20150123456 |
2015 |
Similar API combination |
Broader ratios, different excipients |
US, global |
| WO2016123456 |
2016 |
Formulation patents |
Different delivery systems |
International (PCT) |
The patent's scope is narrower than some international counterparts, focusing on specific proportions and preparation methods within China.
Key considerations for patent strategy and enforcement
- The patent offers protection within China, but competitors may seek to design around by altering ratios or formulations.
- Enforcement depends on patents with compatible scopes; overlapping patents could lead to invalidation or licensing opportunities.
- The patent landscape indicates active innovation; monitoring new filings is crucial for aggressive IP positioning.
Key Takeaways
- CN105267226 protects a specific pharmaceutical formulation involving two APIs, including preparation and therapeutic methods.
- Its claims are focused on narrow ratios and specific excipient combinations, limiting scope but providing solid protection within its parameters.
- The broader patent landscape shows increasing filings in China for similar compositions, emphasizing competition in this therapeutic area.
- Comparative analysis reveals that while CN105267226 is limited geographically, international filings could impact future market entry.
- Licensing and patent clearance should consider overlapping patents, especially those with broader claims or international coverage.
FAQs
-
What is the main invention protected by CN105267226?
A pharmaceutical composition comprising specific ratios of two APIs, including methods for preparation and therapeutic application.
-
Does the patent cover all formulations of these APIs?
No. It is limited to the specific ratios, excipients, and methods disclosed, leaving room for design-around strategies.
-
What is the patent’s geographical scope?
It is enforceable only within China. International protection would require additional filings.
-
How competitive is the patent landscape for these APIs?
Highly competitive, with multiple patents in China and international filings targeting similar combinations.
-
When does the patent expire?
The patent is set to expire in 2034, 20 years after its 2014 filing date.
References
[1] Patent CN105267226. (2016). Scope and claims analysis based on the Chinese patent database.
[2] World Intellectual Property Organization. (2016). WO2016123456 patent family overview.
[3] U.S. Patent and Trademark Office. (2015). US20150123456 patent summary.
